<DOC>
	<DOCNO>NCT01427751</DOCNO>
	<brief_summary>This study evaluate safety efficacy dexamethasone intravitreal implant ( Ozurdex® ) compare ranibizumab ( Lucentis® ) patient branch retinal vein occlusion ( BRVO ) .</brief_summary>
	<brief_title>Safety Efficacy Study Ozurdex® Compared Lucentis® Patients With Branch Retinal Vein Occlusion</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Diagnosis branch retinal vein occlusion least one eye Visual acuity 20/400 20/40 Active eye infection Ocular hypertension control monotherapy ( one medication ) Anticipated need eye surgery study Cataract surgery either eye within 3 month Eye surgery include laser type within 6 month AntiVEGF treatment either eye ( eg , Lucentis® ) within 3 month systemic antiVEGF treatment ( eg , Avastin ) within 6 month Use ocular steroid within 3 month Use steroid ( except inhale intranasal ) within 1 month anticipate use study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>